Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease

被引:30
|
作者
Yang, Yue [1 ]
Keene, C. Dirk [1 ]
Peskind, Elaine R. [2 ,3 ]
Galasko, Douglas R. [4 ]
Hu, Shu-Ching [5 ]
Cudaback, Eiron [1 ]
Wilson, Angela M. [1 ]
Li, Ge [2 ]
Yu, Chang-En [6 ,7 ]
Montine, Kathleen S. [1 ]
Zhang, Jing [1 ]
Baird, Geoffrey S. [1 ,8 ]
Hyman, Bradley T. [9 ]
Montine, Thomas J. [1 ]
机构
[1] Univ Washington, Dept Pathol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA
[3] VA Puget Sound Hlth Care Syst, VA Northwest Network Mental Illness Res Educ & Cl, Seattle, WA USA
[4] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA
[5] Univ Washington, Dept Neurol, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA 98195 USA
[7] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA
[8] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA
[9] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA
关键词
Alzheimer disease; Biomarkers; Cerebrospinal fluid; Cognitive impairment; Neurodegenerative disease; Parkinson disease; APOLIPOPROTEIN-A-I; AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; GENOME-WIDE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; E APOE POLYMORPHISM; TARGETED REPLACEMENT; MEMBRANE-VESICLES; MOUSE MODEL; CIRCULATING MICROPARTICLES;
D O I
10.1097/NEN.0000000000000207
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Human cerebrospinal fluid (CSF) contains diverse lipid particles, including lipoproteins that are distinct from their plasma counterparts and contain apolipoprotein (apo) E isoforms, apoJ, and apoAI, and extracellular vesicles, which can be detected by annexin V binding. The aim of this study was to develop a method to quantify CSF particles and evaluate their relationship to aging and neurodegenerative diseases. We used a flow cytometric assay to detect annexin V-, apoE-, apoAI-, apoJ-, and amyloid (A) (42)-positive particles in CSF from 131 research volunteers who were neurologically normal or had mild cognitive impairment (MCI), Alzheimer disease (AD) dementia, or Parkinson disease. APOE epsilon 4/epsilon 4 participants had CSF apoE-positive particles that were more frequently larger but at an 88% lower level versus those in APOE epsilon 3/epsilon 3 or APOE epsilon 3/epsilon 4 patients; this finding was reproduced in conditioned medium from mouse primary glial cell cultures with targeted replacement of apoE. Cerebrospinal fluid apoE-positive and -amyloid (A(42))-positive particle concentrations were persistently reduced one-third to one-half in middle and older age subjects; apoAI-positive particle concentration progressively increased approximately 2-fold with age. Both apoAI-positive and annexin V-positive CSF particle levels were reduced one-third to one-half in CSF of MCI and/or AD dementia patients versus age-matched controls. Our approach provides new methods to investigate CNS lipid biology in relation to neurodegeneration and perhaps develop new biomarkers for diagnosis or treatment monitoring.
引用
收藏
页码:672 / 687
页数:16
相关论文
共 50 条
  • [21] Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease
    Zetterberg, Henrik
    Lunn, Michael P.
    Herukka, Sanna-Kaisa
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 371 - 376
  • [22] Clinical usefulness of cerebrospinal fluid biomarkers in Alzheimer's disease
    Pena-Bautista, Carmen
    Alvarez-Sanchez, Lourdes
    Pascual, Rosa
    Jose Moreno, Maria
    Baquero, Miguel
    Chafer-Pericas, Consuelo
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (03)
  • [23] Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum
    Cervera-Carles, Laura
    Alcolea, Daniel
    Estanga, Ainara
    Ecay-Torres, Mirian
    Izagirre, Andrea
    Clerigue, Montserrat
    Garcia-Sebastian, Maite
    Villanua, Jorge
    Escalas, Claudia
    Blesa, Rafael
    Martinez-Lage, Pablo
    Lleo, Alberto
    Fortea, Juan
    Clarimon, Jordi
    NEUROBIOLOGY OF AGING, 2017, 53 : 192.e1 - 192.e4
  • [24] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
    Blennow, Kaj
    Zetterberg, Henrik
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 18 (02) : 413 - 417
  • [25] A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium
    Somers, Charisse
    Struyfs, Hanne
    Goossens, Joery
    Niemantsverdriet, Ellis
    Luyckx, Jill
    De Roeck, Naomi
    De Roeck, Ellen
    De Vil, Bart
    Cras, Patrick
    Martin, Jean-Jacques
    De Deyn, Peter-Paul
    Bjerke, Maria
    Engelborghs, Sebastiaan
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 54 (01) : 383 - 395
  • [26] Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease
    Zhang, J
    Goodlett, DR
    Quinn, JF
    Peskind, E
    Kaye, JA
    Zhou, Y
    Pan, C
    Yi, E
    Eng, J
    Wang, Q
    Aebersold, RH
    Montine, TJ
    JOURNAL OF ALZHEIMERS DISEASE, 2005, 7 (02) : 125 - 133
  • [27] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments
    Paraskevas, George P.
    Kapaki, Elisabeth
    BRAIN SCIENCES, 2021, 11 (10)
  • [28] Predictive Modeling of Alzheimer's and Parkinson's Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid
    Hwangbo, Nathan
    Zhang, Xinyu
    Raftery, Daniel
    Gu, Haiwei
    Hu, Shu-Ching
    Montine, Thomas J.
    Quinn, Joseph F.
    Chung, Kathryn A.
    Hiller, Amie L.
    Wang, Dongfang
    Fei, Qiang
    Bettcher, Lisa
    Zabetian, Cyrus P.
    Peskind, Elaine R.
    Li, Ge
    Promislow, Daniel E. L.
    Davis, Marie Y.
    Franks, Alexander
    METABOLITES, 2022, 12 (04)
  • [29] Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease
    Johansson, Per
    Almqvist, Erik G.
    Bjerke, Maria
    Wallin, Anders
    Johansson, Jan-Ove
    Andreasson, Ulf
    Blennow, Kaj
    Zetterberg, Henrik
    Svensson, Johan
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 59 (03) : 1017 - 1026
  • [30] Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease
    Tateno, Fuyuki
    Sakakibara, Ryuji
    Kawai, Takayuki
    Kishi, Masahiko
    Murano, Takeyoshi
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2012, 26 (03) : 213 - 216